Menu

Duesburg Appeals

The article titled 230 Publication Of AIDS Article Spurs Debate Over Peer Review” (The Scientist, April 3, 1989, page 1), described the scrutiny that my thesis—that HIV is not the cause of AIDS— was subjected to prior to its publication in PNAS (86:755-64, 1989). This report was accurate, fair, and open. However, I was disappointed to read that retrovirologists Howard Temin and Harold Ginsberg stated to The Scientist that my article “still contained errors,” despite

Oct 16, 1989
Peter Duesberg

The article titled 230 Publication Of AIDS Article Spurs Debate Over Peer Review” (The Scientist, April 3, 1989, page 1), described the scrutiny that my thesis—that HIV is not the cause of AIDS— was subjected to prior to its publication in PNAS (86:755-64, 1989). This report was accurate, fair, and open. However, I was disappointed to read that retrovirologists Howard Temin and Harold Ginsberg stated to The Scientist that my article “still contained errors,” despite seven reviews, including three anonymous ones. Since I like nothing more than to correct my own errors—particularly when they concern such an important subject as AIDS—I have written to both Temin and Ginsberg, asking them to please identify these errors. Temin responded to the two letters I sent him by saying he had no time to identify these errors, and Ginsberg did not reply at all. I herein repeat my request that Temin and Ginsberg substantiate their claims that my published PNAS paper still contained errors.

PETER DUESBERG
Department of Molecular Biology
University of California
Berkeley, Calif.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.